Literature DB >> 25313223

Antimalarial activity of granzyme B and its targeted delivery by a granzyme B-single-chain Fv fusion protein.

Stephanie Kapelski1, Melanie de Almeida1, Rainer Fischer1, Stefan Barth2, Rolf Fendel3.   

Abstract

We present here the first evidence that granzyme B acts against Plasmodium falciparum (50% inhibitory concentration [IC50], 1,590 nM; 95% confidence interval [95% CI], 1,197 to 2,112 nM). We created a novel antimalarial fusion protein consisting of granzyme B fused to a merozoite surface protein 4 (MSP4)-specific single-chain Fv protein (scFv), which targets the enzyme to infected erythrocytes, with up to an 8-fold reduction in the IC50 (176 nM; 95% CI, 154 to 202 nM). This study confirms the therapeutic efficacies of recombinant antibody-mediated antimalarial immunotherapeutics based on granzyme B.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25313223      PMCID： PMC4291407          DOI： 10.1128/AAC.04190-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  35 in total

1.  A protein on Plasmodium falciparum-infected erythrocytes functions as a transferrin receptor.

Authors:  M H Rodriguez; M Jungery
Journal:  Nature       Date:  1986 Nov 27-Dec 3       Impact factor: 49.962

2.  Identifying merozoite surface protein 4 and merozoite surface protein 7 Plasmodium falciparum protein family members specifically binding to human erythrocytes suggests a new malarial parasite-redundant survival mechanism.

Authors:  Yesid Garcia; Alvaro Puentes; Hernando Curtidor; Gladys Cifuentes; Claudia Reyes; Jose Barreto; Armando Moreno; Manuel E Patarroyo
Journal:  J Med Chem       Date:  2007-10-18       Impact factor: 7.446

3.  Cell surface receptor directed targeting of toxin to human malaria parasite, Plasmodium falciparum.

Authors:  N Surolia; S Misquith
Journal:  FEBS Lett       Date:  1996-10-28       Impact factor: 4.124

4.  A possible role for natural killer cells in providing protection against Plasmodium berghei in early stages of infection.

Authors:  J B Solomon; M G Forbes; G R Solomon
Journal:  Immunol Lett       Date:  1985       Impact factor: 3.685

5.  A second merozoite surface protein (MSP-4) of Plasmodium falciparum that contains an epidermal growth factor-like domain.

Authors:  V M Marshall; A Silva; M Foley; S Cranmer; L Wang; D J McColl; D J Kemp; R L Coppel
Journal:  Infect Immun       Date:  1997-11       Impact factor: 3.441

6.  Natural killer (NK) cell-mediated cytolysis of Plasmodium falciparum-infected human red blood cells in vitro.

Authors:  Elie Mavoungou; Adrian J F Luty; Peter G Kremsner
Journal:  Eur Cytokine Netw       Date:  2003 Jul-Sep       Impact factor: 2.737

7.  Artemisinin resistance in Plasmodium falciparum malaria.

Authors:  Arjen M Dondorp; François Nosten; Poravuth Yi; Debashish Das; Aung Phae Phyo; Joel Tarning; Khin Maung Lwin; Frederic Ariey; Warunee Hanpithakpong; Sue J Lee; Pascal Ringwald; Kamolrat Silamut; Mallika Imwong; Kesinee Chotivanich; Pharath Lim; Trent Herdman; Sen Sam An; Shunmay Yeung; Pratap Singhasivanon; Nicholas P J Day; Niklas Lindegardh; Duong Socheat; Nicholas J White
Journal:  N Engl J Med       Date:  2009-07-30       Impact factor: 91.245

8.  Parasite maturation and host serum iron influence the labile iron pool of erythrocyte stage Plasmodium falciparum.

Authors:  Martha Clark; Nancy C Fisher; Raj Kasthuri; Carla Cerami Hand
Journal:  Br J Haematol       Date:  2013-02-08       Impact factor: 6.998

9.  Targeted delivery of human pro-apoptotic enzymes to tumor cells: In vitro studies describing a novel class of recombinant highly cytotoxic agents.

Authors:  Yuying Liu; Lawrence H Cheung; Walter N Hittelman; Michael G Rosenblum
Journal:  Mol Cancer Ther       Date:  2003-12       Impact factor: 6.261

10.  Plasmodium falciparum-infected erythrocytes induce granzyme B by NK cells through expression of host-Hsp70.

Authors:  Evelyn Böttger; Gabriele Multhoff; Jürgen F J Kun; Meral Esen
Journal:  PLoS One       Date:  2012-03-15       Impact factor: 3.240
View more
  13 in total

1.  A High Yield and Cost-efficient Expression System of Human Granzymes in Mammalian Cells.

Authors:  Farokh Dotiwala; Isabelle Fellay; Luis Filgueira; Denis Martinvalet; Judy Lieberman; Michael Walch
Journal:  J Vis Exp       Date:  2015-06-10       Impact factor: 1.355

Review 2.  Engineered antibody fusion proteins for targeted disease therapy.

Authors:  Aliyah B Silver; Elissa K Leonard; Joseph R Gould; Jamie B Spangler
Journal:  Trends Pharmacol Sci       Date:  2021-10-25       Impact factor: 14.819

3.  γδ T Cells Kill Plasmodium falciparum in a Granzyme- and Granulysin-Dependent Mechanism during the Late Blood Stage.

Authors:  Maria Andrea Hernández-Castañeda; Katharina Happ; Filippo Cattalani; Alexandra Wallimann; Marianne Blanchard; Isabelle Fellay; Brigitte Scolari; Nils Lannes; Smart Mbagwu; Benoît Fellay; Luis Filgueira; Pierre-Yves Mantel; Michael Walch
Journal:  J Immunol       Date:  2020-02-17       Impact factor: 5.422

4.  Isolation, production and characterization of fully human monoclonal antibodies directed to Plasmodium falciparum MSP10.

Authors:  Dominika J Maskus; Susanne Bethke; Melanie Seidel; Stephanie Kapelski; Otchere Addai-Mensah; Alexander Boes; Güven Edgü; Holger Spiegel; Andreas Reimann; Rainer Fischer; Stefan Barth; Torsten Klockenbring; Rolf Fendel
Journal:  Malar J       Date:  2015-07-16       Impact factor: 2.979

5.  Fast track antibody V-gene rescue, recombinant expression in plants and characterization of a PfMSP4-specific antibody.

Authors:  Stephanie Kapelski; Alexander Boes; Holger Spiegel; Melanie de Almeida; Torsten Klockenbring; Andreas Reimann; Rainer Fischer; Stefan Barth; Rolf Fendel
Journal:  Malar J       Date:  2015-02-05       Impact factor: 2.979

6.  Characterization of a novel inhibitory human monoclonal antibody directed against Plasmodium falciparum Apical Membrane Antigen 1.

Authors:  Dominika J Maskus; Michał Królik; Susanne Bethke; Holger Spiegel; Stephanie Kapelski; Melanie Seidel; Otchere Addai-Mensah; Andreas Reimann; Torsten Klockenbring; Stefan Barth; Rainer Fischer; Rolf Fendel
Journal:  Sci Rep       Date:  2016-12-21       Impact factor: 4.379

7.  Generation of an artificial human B cell line test system using Transpo-mAbTM technology to evaluate the therapeutic efficacy of novel antigen-specific fusion proteins.

Authors:  Diana Klose; Mira Woitok; Judith Niesen; Roger R Beerli; Ulf Grawunder; Rainer Fischer; Stefan Barth; Rolf Fendel; Thomas Nachreiner
Journal:  PLoS One       Date:  2017-07-13       Impact factor: 3.240

Review 8.  Designing the Sniper: Improving Targeted Human Cytolytic Fusion Proteins for Anti-Cancer Therapy via Molecular Simulation.

Authors:  Anna Bochicchio; Sandra Jordaan; Valeria Losasso; Shivan Chetty; Rodrigo Casasnovas Perera; Emiliano Ippoliti; Stefan Barth; Paolo Carloni
Journal:  Biomedicines       Date:  2017-02-17

Review 9.  Macromolecular Conjugate and Biological Carrier Approaches for the Targeted Delivery of Antibiotics.

Authors:  Nhan Dai Thien Tram; Pui Lai Rachel Ee
Journal:  Antibiotics (Basel)       Date:  2017-07-04

Review 10.  Heat Shock Proteins as Immunomodulants.

Authors:  Tawanda Zininga; Lebogang Ramatsui; Addmore Shonhai
Journal:  Molecules       Date:  2018-11-01       Impact factor: 4.411
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.